Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
McKinsey
Express Scripts
Boehringer Ingelheim
Baxter

Last Updated: January 27, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Reparixin

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Reparixin?

Reparixin is an investigational drug.

There have been 8 clinical trials for Reparixin. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2012.

The most common disease conditions in clinical trials are Breast Neoplasms, Reperfusion Injury, and Ischemia. The leading clinical trial sponsors are Dompé Farmaceutici S.p.A, PRA Health Sciences, and [disabled in preview].

There are eight US patents protecting this investigational drug and one hundred and sixty-eight international patents.

Recent Clinical Trials for Reparixin
TitleSponsorPhase
A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast CancerPRA Health SciencesPhase 2
A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast CancerDompé Farmaceutici S.p.APhase 2
Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver TransplantationDompé Farmaceutici S.p.APhase 2

See all Reparixin clinical trials

Clinical Trial Summary for Reparixin

Top disease conditions for Reparixin
Top clinical trial sponsors for Reparixin

See all Reparixin clinical trials

US Patents for Reparixin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Reparixin   Start Trial Use of (R)--ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs Dompe Pha.r.ma S.p.A. (L'Aquila, IT)   Start Trial
Reparixin   Start Trial 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them Dompe Pha.R.Ma S.p.A. (L'Aquila, IT)   Start Trial
Reparixin   Start Trial 2-arylpropionic acid derivatives and pharmaceutical compositions containing them DompePHA.R.MA S.p.A. (L'Aquila, IT)   Start Trial
Reparixin   Start Trial 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Reparixin

Drugname Country Document Number Estimated Expiration Related US Patent
Reparixin Austria 304846 2021-02-02   Start Trial
Reparixin Australia 2002250869 2021-02-02   Start Trial
Reparixin Brazil 0206804 2021-02-02   Start Trial
Reparixin Brazil PI0206804 2021-02-02   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Mallinckrodt
McKesson
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.